Citigroup Inc. Has $181.85 Million Stock Holdings in Stryker Corporation $SYK

Citigroup Inc. boosted its position in Stryker Corporation (NYSE:SYK) by 7.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 491,919 shares of the medical technology company’s stock after buying an additional 35,853 shares during the period. Citigroup Inc. owned approximately 0.13% of Stryker worth $181,848,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SYK. Brighton Jones LLC grew its position in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new position in shares of Stryker during the second quarter valued at about $205,000. Brookstone Capital Management increased its position in shares of Stryker by 10.6% during the second quarter. Brookstone Capital Management now owns 2,496 shares of the medical technology company’s stock worth $988,000 after acquiring an additional 239 shares in the last quarter. Strategic Blueprint LLC raised its holdings in shares of Stryker by 79.3% in the 2nd quarter. Strategic Blueprint LLC now owns 2,350 shares of the medical technology company’s stock worth $930,000 after acquiring an additional 1,039 shares during the last quarter. Finally, Sage Mountain Advisors LLC lifted its position in Stryker by 13.6% in the 2nd quarter. Sage Mountain Advisors LLC now owns 1,976 shares of the medical technology company’s stock valued at $782,000 after acquiring an additional 236 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Evercore set a $390.00 price objective on Stryker in a report on Monday, January 5th. The Goldman Sachs Group set a $399.00 price target on Stryker in a report on Friday, January 9th. William Blair initiated coverage on Stryker in a research note on Friday. They set an “outperform” rating on the stock. Truist Financial cut their price objective on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Finally, Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price for the company in a report on Tuesday, January 6th. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $426.94.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 5.90% of the company’s stock.

Stryker Trading Up 2.0%

Shares of Stryker stock opened at $380.15 on Friday. The firm has a market cap of $145.48 billion, a PE ratio of 45.26, a P/E/G ratio of 2.22 and a beta of 0.87. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The stock has a fifty day moving average price of $360.05 and a 200-day moving average price of $368.86.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.01 earnings per share. Equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio is presently 41.90%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.